24Jul/13

Genentech's Obinutuzumab (GA101) Delayed Disease Progression Longer … – DailyFinance

Genentech’s Obinutuzumab (GA101) Delayed Disease Progression Longer
DailyFinance
monitoring committee determined that the study met its primary endpoint showing that GA101 plus chlorambucil helped people live significantly longer without their disease worsening (progression-free survival; PFS) compared to Rituxan® (rituximab
Roche antibody tops Rituxan in blood cancer CLLPMLiVE
Genentech Trumpets Phase III Results for CLL CandidateGenetic Engineering News

all 11 news articles »